Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease.

ABSTRACT:

Background & aims

Alcohol-related liver disease (ALD) comprises different liver disorders which impose a health care issue. ALD and particularly alcoholic steatohepatitis, an acute inflammatory condition, cause a substantial morbidity and mortality as effective treatment options remain elusive. Inflammation in ALD is fuelled by macrophages (Kupffer cells [KCs]) which are activated by intestinal pathogen associated molecular patterns, eg lipopolysaccharide (LPS), disseminated beyond a defective intestinal barrier. We hypothesized that the immunomodulator dimethyl-fumarate (DMF), which is approved for the treatment of human inflammatory conditions such as multiple sclerosis or psoriasis, ameliorates the course of experimental ALD.

Methods

Dimethyl-fumarate or vehicle was orall

SUBMITTER: Sangineto M 

PROVIDER: S-EPMC7383968 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature